HELP (Helus Pharma) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 27, 2026)


HELP Helus Pharma Inc HELP
22 GF Score
Price $6.48
! 1 Warning Sign
View Full Analysis

What is Helus Pharma Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Helus Pharma's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

HELP vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Helus Pharma's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Helus Pharma Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helus Pharma's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Helus Pharma's Margin of Safety % (DCF Earnings Based) falls into.


HELP
22GF Score
Helus Pharma Inc HELP
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma Business Description

Other Exchanges R7E:GermanyHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
22GF Score

Get the complete analysis for HELP

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.48
Price